CervoMed CRVO
NASDAQ CRVO
$1.37 -0.06 (-4.20%)
At close: Nov 10, 2026 · 4:00 PM EST

CervoMed (CRVO) Current Deferred Revenue (2023 - 2024)

Updated

CervoMed's Current Deferred Revenue came in at $1.4 million for Q2 2024, up 144.8% from the prior quarter.

Analysis

CervoMed (CRVO) Current Deferred Revenue (2023 - 2024) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,264.65 Bn 1,238.27 Bn 20.46 Bn
2 Johnson & Johnson 677.74 Bn 597.60 Bn 17.30 Bn
3 AbbVie 517.10 Bn 485.11 Bn 13.12 Bn
4 Merck 362.23 Bn 325.17 Bn 13.19 Bn
5 Novartis Ag 315.90 Bn 276.16 Bn 11.24 Bn
6 Astrazeneca 289.40 Bn 266.24 Bn 12.86 Bn
7 Amgen 249.90 Bn 201.56 Bn 7.58 Bn
8 Gilead Sciences 209.15 Bn 184.26 Bn 6.73 Bn
9 Pfizer 165.88 Bn 113.23 Bn 12.56 Bn
10 CervoMed 14.36 Mn -71.66 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2024 1.40 Mn
Mar 31, 2024 572,475.00
Sep 30, 2023 547,051.00
API Access

CervoMed Current Deferred Revenue API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=current-deferred-revenue&ticker=CRVO&period=max&api_key=YOUR_API_KEY